Longitudinal whole blood transcriptomic analysis characterizes neutrophil activation and interferon signaling in moderate and severe COVID-19.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
26 06 2023
Historique:
received: 17 10 2022
accepted: 24 06 2023
medline: 28 6 2023
pubmed: 27 6 2023
entrez: 26 6 2023
Statut: epublish

Résumé

A maladaptive inflammatory response has been implicated in the pathogenesis of severe COVID-19. This study aimed to characterize the temporal dynamics of this response and investigate whether severe disease is associated with distinct gene expression patterns. We performed microarray analysis of serial whole blood RNA samples from 17 patients with severe COVID-19, 15 patients with moderate disease and 11 healthy controls. All study subjects were unvaccinated. We assessed whole blood gene expression patterns by differential gene expression analysis, gene set enrichment, two clustering methods and estimated relative leukocyte abundance using CIBERSORT. Neutrophils, platelets, cytokine signaling, and the coagulation system were activated in COVID-19, and this broad immune activation was more pronounced in severe vs. moderate disease. We observed two different trajectories of neutrophil-associated genes, indicating the emergence of a more immature neutrophil phenotype over time. Interferon-associated genes were strongly enriched in early COVID-19 before falling markedly, with modest severity-associated differences in trajectory. In conclusion, COVID-19 necessitating hospitalization is associated with a broad inflammatory response, which is more pronounced in severe disease. Our data suggest a progressively more immature circulating neutrophil phenotype over time. Interferon signaling is enriched in COVID-19 but does not seem to drive severe disease.

Identifiants

pubmed: 37365222
doi: 10.1038/s41598-023-37606-y
pii: 10.1038/s41598-023-37606-y
pmc: PMC10293211
doi:

Substances chimiques

Interferons 9008-11-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10368

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Nat Immunol. 2021 Jan;22(1):32-40
pubmed: 33277638
JCI Insight. 2021 May 10;6(9):
pubmed: 33986193
J Exp Med. 2021 Aug 2;218(8):
pubmed: 34128959
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
J Intensive Care Med. 2022 Jul;37(7):857-869
pubmed: 34672824
J Immunol. 2021 May 1;206(9):2146-2159
pubmed: 33846224
Cell Host Microbe. 2012 Sep 13;12(3):324-33
pubmed: 22980329
Circulation. 2020 Dec;142(22):2128-2137
pubmed: 33058695
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
Front Immunol. 2021 Oct 04;12:735922
pubmed: 34671353
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Sci Rep. 2018 Oct 10;8(1):15107
pubmed: 30305653
iScience. 2021 Oct 22;24(10):103115
pubmed: 34522848
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
EBioMedicine. 2021 Mar;65:103262
pubmed: 33691247
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Genome Med. 2021 Jan 13;13(1):7
pubmed: 33441124
iScience. 2021 Jul 23;24(7):102711
pubmed: 34127958
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Front Immunol. 2018 Sep 27;9:2129
pubmed: 30356906
NAR Genom Bioinform. 2023 Mar 03;5(1):lqad020
pubmed: 36879899
Immunity. 2021 Nov 9;54(11):2650-2669.e14
pubmed: 34592166
Cell Rep Med. 2022 Oct 18;3(10):100779
pubmed: 36208629
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Front Immunol. 2022 Nov 16;13:970287
pubmed: 36466858
Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198
pubmed: 31066453
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
Cell Rep Med. 2020 Dec 26;2(1):100166
pubmed: 33521697
Blood Adv. 2021 Mar 9;5(5):1164-1177
pubmed: 33635335
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926098
Nat Immunol. 2020 Dec;21(12):1506-1516
pubmed: 33028979
Intensive Care Med Exp. 2020 Dec 11;8(1):75
pubmed: 33306162
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Cell. 2020 Dec 10;183(6):1479-1495.e20
pubmed: 33171100
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Cell Mol Immunol. 2020 Jul;17(7):771-772
pubmed: 32467616
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Eur J Immunol. 2020 Sep;50(9):1283-1294
pubmed: 32910469
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32886755
EBioMedicine. 2020 Aug;58:102925
pubmed: 32745993
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
Circulation. 2020 Sep 22;142(12):1176-1189
pubmed: 32755393
Nat Cell Biol. 2021 May;23(5):538-551
pubmed: 33972731
Sci Adv. 2022 Jun 3;8(22):eabm2510
pubmed: 35648852
Stat Appl Genet Mol Biol. 2013 Oct 1;12(5):637-52
pubmed: 23942354
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059

Auteurs

Christian Prebensen (C)

Department of Infectious Diseases, Oslo University Hospital, Kirkeveien 166, 0450, Oslo, Norway. christian.prebensen@medisin.uio.no.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway. christian.prebensen@medisin.uio.no.

Yohan Lefol (Y)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Microbiology, University of Oslo, Oslo, Norway.

Peder L Myhre (PL)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Cardiology, Akershus University Hospital, Lørenskog, Norway.

Torben Lüders (T)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway.

Christine Jonassen (C)

Center for Laboratory Medicine, Østfold Hospital Trust, Grålum, Norway.

Anita Blomfeldt (A)

Department of Microbiology and Infection Control, Akershus University Hospital, Lørenskog, Norway.

Torbjørn Omland (T)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Cardiology, Akershus University Hospital, Lørenskog, Norway.

Hilde Nilsen (H)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Microbiology, University of Oslo, Oslo, Norway.

Jan-Erik Berdal (JE)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Infectious Diseases, Akershus University Hospital, Lørenskog, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH